Quest Diagnostics Inc (DGX.N) will acquire Celera Corp (CRA.O) for about $657 million in cash to gain access to its smaller rival's gene-based testing technology. Quest will pay Celera shareholders $8 per share, a premium of 28 percent to Celera's Thursday's (3/17/11) close of $6.27. Celera shares, which last traded at $8 levels in June 2009, were up 27 percent at $7.98 premarket on Friday (3/18/11).

If you are a current shareholder and would like to discuss your options of exercising your rights as a shareholder, which include ensuring that the company is getting the highest possible price for the company, and that the board of directors will act in the best interest of the shareholders, please contact us.

Please submit the following information so we can determine if you qualify for the suit. If you don't know all the specific details, partial information is also acceptable.